Open Journal of Psychiatry
Vol.5 No.2(2015), Paper ID 55546, 9
pages
DOI:10.4236/ojpsych.2015.52022
Long-Term, Open-Label, Safety Study of Edivoxetine as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment in Japan
Emel Serap Monkul, Mark Bangs, Keita Asato, Masashi Takahashi, Yasushi Takita, Mary Anne Dellva, Jonna Ahl, Celine Goldberger
Eli Lilly and Company, Indianapolis, IN, USA
Eli Lilly and Company, Indianapolis, IN, USA
Eli Lilly Japan K.K. Office, Kobe, Japan
Eli Lilly Japan K.K. Office, Kobe, Japan
Eli Lilly Japan K.K. Office, Kobe, Japan
Eli Lilly and Company, Indianapolis, IN, USA
Eli Lilly and Company, Indianapolis, IN, USA
Eli Lilly and Company, Indianapolis, IN, USA
Copyright © 2015 Emel Serap Monkul, Mark Bangs, Keita Asato, Masashi Takahashi, Yasushi Takita, Mary Anne Dellva, Jonna Ahl, Celine Goldberger et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Monkul, E. , Bangs, M. , Asato, K. , Takahashi, M. , Takita, Y. , Dellva, M. , Ahl, J. and Goldberger, C. (2015) Long-Term, Open-Label, Safety Study of Edivoxetine as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment in Japan.
Open Journal of Psychiatry,
5, 186-194. doi:
10.4236/ojpsych.2015.52022.